Selurampanel
- Generic Name
- Selurampanel
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N5O4S
- CAS Number
- 912574-69-7
- Unique Ingredient Identifier
- 7WG1MR7DAR
- Background
Selurampanel has been investigated in Adrenocortical Adenoma and Sarcoma, Endometrial Stromal.
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
- Conditions
- Endometrial Stromal SarcomasAdrenocortical Adenoma
- Interventions
- Procedure: MRI, CT or ultrasound was permitted if MRI was contraindicatedProcedure: Dexamethasone Supression TestProcedure: SonogramProcedure: Biopsy
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT02150213
- Locations
- 🇸🇰
Novartis Investigative Site, Banska Bystrica, Slovakia
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
- Conditions
- Muscle Spasticity Due to Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01649050
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
- Conditions
- Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01617941
Phase II BGG492 Capsule Extension for Partial Epilepsy
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01338805
- Locations
- 🇸🇰
Novartis Investigative Site, Kosice, Slovakia
Study of BGG492 in Patients With Chronic Subjective Tinnitus
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT01302873
- Locations
- 🇳🇱
Novartis Investigative Site, Groningen, Netherlands
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis
- Registration Number
- NCT01167335
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Epilepsy Care Specialists, S.C., Milwaukee, Wisconsin, United States
🇪🇸Novartis Investigative Site, Barcelona, Spain
Efficacy and Safety of BGG492 in the Treatment of Migraine
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00892203
- Locations
- 🇺🇸
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140, Glendale, California, United States
🇺🇸California Clinical Trials, 15625 Lakewood Boulevard, Paramount, California, United States
🇩🇪Novartis Investigator Site, Munich, Germany
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00784212
- Locations
- 🇩🇪
Novartis Investigator Site, Radeberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.